(4-amino-3-fluorophenyl)pyrrolidin-1-ylmethanone | 209960-85-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (4-amino-3-fluorophenyl)pyrrolidin-1-ylmethanone
• 英文别名: (4-amino-3-fluoro-phenyl)(pyrrolidin-1-yl)methanone；2-fluoro-4-(pyrrolidin-1-yl-carbonyl)-aniline；(4-amino-3-fluorophenyl)-pyrrolidin-1-ylmethanone
• CAS: 209960-85-0
• 化学式: C₁₁H₁₃FN₂O
• 分子量: 208.235
• InChiKey: BSUDGIBVPWWBEC-UHFFFAOYSA-N

物化性质

• 沸点：
  388.4±32.0 °C(Predicted)
• 密度：
  1.275±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  46.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (4-amino-3-fluorophenyl)pyrrolidin-1-ylmethanone 在 三甲基铝 、 tin(ll) chloride 作用下， 以 二氯甲烷 为溶剂， 生成 1-(3-Amino-4-chlorophenyl)-N-[2-fluoro-4-(1-pyrrolidinylcarbonyl)phenyl]-1H-tetrazole-5-carboxamide
  参考文献：
  名称：

  Nonbenzamidine tetrazole derivatives as factor Xa inhibitors

  摘要：

  Factor Xa (fXa) is an important serine protease that holds the central position linking the intrinsic and extrinsic activation mechanisms in the blood coagulation cascade. Therefore, inhibition of fXa has potential therapeutic applications in the treatments of both arterial and venous thrombosis. Herein we describe a series of tetrazole fXa inhibitors containing benzamidine mimics as the P, substrate, of which the aminobenzisoxazole moiety was found to be the most potent benzamidine mimic. SR374 (12) inhibits fXa with a K-i value of 0.35 nM and is very selective for fXa over thrombin and trypsin. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00951-4
• 作为产物：
  描述：

  3-氟-4-硝基苯甲酰氯 在 palladium on activated charcoal 氢气 作用下， 生成 (4-amino-3-fluorophenyl)pyrrolidin-1-ylmethanone
  参考文献：
  名称：

  Nonbenzamidine tetrazole derivatives as factor Xa inhibitors

  摘要：

  Factor Xa (fXa) is an important serine protease that holds the central position linking the intrinsic and extrinsic activation mechanisms in the blood coagulation cascade. Therefore, inhibition of fXa has potential therapeutic applications in the treatments of both arterial and venous thrombosis. Herein we describe a series of tetrazole fXa inhibitors containing benzamidine mimics as the P, substrate, of which the aminobenzisoxazole moiety was found to be the most potent benzamidine mimic. SR374 (12) inhibits fXa with a K-i value of 0.35 nM and is very selective for fXa over thrombin and trypsin. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00951-4

文献信息

• NOVEL PYRROLOÝ2,3-d¨PYRIMIDINE COMPOUND
  申请人：Mitsubishi Tanabe Pharma Corporation

  公开号：EP2390254A1

  公开（公告）日：2011-11-30

  Disclosed is a novel pyrrolo[2,3-d]pyrimidine compound represented by formula [I] or a pharmacologically acceptable salt thereof, which has a GPR119 receptor agonistic activity and is useful for a pharmaceutical. In formula [I], E represents a group represented by formula: -NH-, or the like; ring A represents a 6-membered aromatic ring which may contain 1 to 2 nitrogen atoms as heteroatoms (the aromatic ring may be substituted by a halogen atom, a group represented by formula: -CONRaRb, or the like; Ra and Rb are the same or different and independently represent hydrogen, alkyl, hydroxyalkyl, or the like); R1 represents an acyl group or the like; and R2 represents a halogen atom or a cyano group.

  揭示了一种新型吡咯并[2,3-d]嘧啶化合物，其表示为式[I]或其药理学上可接受的盐，具有GPR119受体激动活性，并且对制药有用。在式[I]中，E代表由式表示的基团：-NH-，或类似基团；环A代表可能含有1至2个氮原子作为杂原子的6元芳香环（芳香环可能被卤素原子、由式表示的基团：-CONRaRb，或类似基团取代；Ra和Rb相同或不同且独立地代表氢、烷基、羟基烷基，或类似基团）；R1代表酰基团或类似基团；R2代表卤素原子或氰基。
• Guanidine mimics as factor Xa inhibitors
  申请人：DuPont Pharmaceuticals Company

  公开号：US06339099B1

  公开（公告）日：2002-01-15

  The present application describes nitrogen containing heteroaromatics and derivatives thereof of formula I: or pharmaceutically acceptable salt forms thereof, wherein rings D—E represent guanidine mimics, which are useful as inhibitors of factor Xa.

  本申请描述了含氮杂环化合物及其衍生物的化学式I：或其药用可接受的盐形式，其中环D—E代表胍嘧啶模拟物，这些化合物可作为凝血因子Xa的抑制剂。
• [DE] SUBSTITUIERTE THIOPHENCARBONSÄUREAMIDE, DEREN HERSTELLUNG UND DEREN VERWENDUNG ALS ARZNEIMITTEL<br/>[EN] SUBSTITUTED THIOPHEN-CARBOXYLIC ACID AMIDES, THE PRODUCTION AND THE USE THEREOF IN THE FORM OF A DRUG<br/>[FR] AMIDES SUBSTITUES DE L'ACIDE THIOPHENE-CARBOXYLIQUE, LEUR PRODUCTION ET LEUR UTILISATION COMME MEDICAMENT
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2005111014A1

  公开（公告）日：2005-11-24

  Gegenstand der vorliegenden Erfindung sind neue substituierte Thiophen-2-carbonsäureamide der allgemeinen Formel (I), in der A, und R1 bis R8c wie in Anspruch 1 definiert sind, deren Tautomere, deren Enantiomere, deren Diastereomere, deren Gemische und deren Salze, insbesondere deren physiologisch verträgliche Salze mit anorganischen oder organischen Säuren oder Basen, welche wertvolle Eigenschaften aufweisen.

  本发明涉及新的一般式(I)的取代噻吩-2-羧酰胺，其中A和R1至R8c如权利要求1中定义的，其互变异构体、对映体、非对映体、混合物及盐，特别是其与无机或有机酸或碱形成的生理相容性盐，具有有价值的特性。
• Benzimidazole-derivatives as factor Xa inhibitors
  申请人：Nazare Marc

  公开号：US20050009829A1

  公开（公告）日：2005-01-13

  The present invention relates to compounds of the formula I, wherein R 0 , R 1 , R 2 , Q, V, G and M are as defined herein. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

  本发明涉及式I的化合物，其中R0、R1、R2、Q、V、G和M如本文所定义。式I的化合物是有价值的药理活性化合物。它们表现出强烈的抗血栓作用，适用于心血管疾病如血栓栓塞病或再狭窄的治疗和预防。它们是血凝酶酶因子Xa（FXa）和/或因子VIIa（FVIIa）的可逆抑制剂，并且通常可以应用于存在因子Xa和/或因子VIIa的不良活性或者需要抑制因子Xa和/或因子VIIa以治疗或预防的情况。此外，本发明还涉及制备式I的化合物的方法，它们的使用，尤其是作为药物的活性成分，以及包含它们的制药制剂。
• Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
  申请人：Pfizer Inc.

  公开号：US20040167131A1

  公开（公告）日：2004-08-26

  This invention discloses amino acid derivatives which display inhibitory effects on the serine protease factor Xa. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, methods for the preparation of the compounds, and methods of using them as therapeutic agents for treating or preventing disease states in mammals characterized by abnormal thrombosis.

  本发明揭示了一种氨基酸衍生物，其显示出对丝氨酸蛋白酶Xa的抑制效果。该发明还揭示了该化合物的药学上可接受的盐、包含该化合物或其盐的药学上可接受的组合物，制备该化合物的方法以及将其用作治疗或预防哺乳动物异常血栓病状态的治疗剂的方法。